Read by QxMD icon Read

Atypical dementia

Dae Lim Koo, Jee Young Lee, Hyunwoo Nam
OBJECTIVE: Rapid eye movement sleep behavior disorder (RBD) is a common sleep disturbance in patients with neurodegenerative disorders. We aimed to compare sleep parameters among the different types of RBD patients. METHODS: A total of 122 patients with dream enactment behavior were screened. Of these, 92 patients who were diagnosed with RBD by polysomnography were included in this study. Enrolled patients with RBD were classified into four groups based on the following diagnoses: idiopathic RBD (iRBD); RBD with Parkinson disease (PD-RBD); multiple system atrophy (MSA) with RBD (MSA-RBD); and dementia with Lewy bodies (DLB) with RBD (DLB-RBD)...
June 28, 2018: Sleep Medicine
Daniela Monaco, Daniela Berg, Astrid Thomas, Vincenzo Di Stefano, Filomena Barbone, Michela Vitale, Camilla Ferrante, Laura Bonanni, Marta Di Nicola, Tonia Garzarella, Luciano Paolo Marchionno, Giovanni Malferrari, Rocco Di Mascio, Marco Onofrj, Raffaella Franciotti
Transcranial sonography (TCS) is a noninvasive, easily performed, and commonly available neuroimaging technique useful for the study of brain parenchyma in movement disorders. This tool has been increasingly used in the diagnosis of Parkinson's disease and atypical parkinsonism. The aim of the study was to evaluate the applicability of this technique as supportive tool in the early diagnosis of movement disorders. We performed TCS on 315 individuals which were diagnosed as healthy controls or affected by idiopathic Parkinson's disease, monogenetic subtypes of Parkinson's disease, atypical parkinsonism, and Dementia with Lewy bodies...
August 7, 2018: Neurological Sciences
Hirohisa Watanabe, Yuichi Riku, Kazuhiro Hara, Kazuya Kawabata, Tomohiko Nakamura, Mizuki Ito, Masaaki Hirayama, Mari Yoshida, Masahisa Katsuno, Gen Sobue
Multiple system atrophy (MSA) is an adult-onset, progressive neurodegenerative disorder. Patients with MSA show various phenotypes during the course of their illness, including parkinsonism, cerebellar ataxia, autonomic failure, and pyramidal signs. Patients with MSA sometimes present with isolated autonomic failure or motor symptoms/ signs. The median duration from onset to the concomitant appearance of motor and autonomic symptoms is approximately 2 years but can range up to 14 years. As the presence of both motor and autonomic symptoms is essential for the current diagnostic criteria, early diagnosis is difficult when patients present with isolated autonomic failure or motor symptoms/signs...
August 9, 2018: Journal of Movement Disorders
K Egger, M Rijntjes
The differential diagnosis of atypical dementia remains difficult. The use of positron emission tomography (PET) still represents the gold standard for imaging diagnostics. According to the current evidence, however, magnetic resonance imaging (MRI) is almost equal to fluorodeoxyglucose (FDG)-PET, but only when using new big data and machine learning methods. In cases of atypical dementia, especially in younger patients and for follow-up, MRI is preferable to computed tomography (CT). In the clinical routine, promising MRI procedures are e...
August 3, 2018: Der Nervenarzt
R Laforce, J P Soucy, L Sellami, C Dallaire-Théroux, F Brunet, D Bergeron, B L Miller, R Ossenkoppele
Molecular imaging techniques using 18 F-fluorodeoxyglucose, amyloid tracers, and, more recently, tau ligands have taken dementia research by storm and undoubtedly improved our understanding of neurodegenerative diseases. The ability to image in vivo the pathological substrates of degenerative diseases and visualize their downstream impact has led to improved models of pathogenesis, better differential diagnosis of atypical conditions, as well as focused subject selection and monitoring of treatment in clinical trials aimed at delaying or preventing the symptomatic phase of Alzheimer's disease...
July 17, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Joseph H Friedman
INTRODUCTION: Pimavanserin (Pim) is a 5HT2A inverse agonist that is the only Food and Drug Administration-approved treatment for Parkinson disease (PD) psychosis. The published open-label experience is limited. METHODS: This report is a chart review of all patients who were started on the drugs since the one earlier report on 15 patients. All patients were included, whether or not they completed 6 weeks of treatment, the time required for maximum benefit found in the published phase 3 trial...
July 13, 2018: Clinical Neuropharmacology
X J Xue, R L He, W X Li, J W Xin, Q Y Ye, X C Chen, X D Pan
Objective: To assess the safety of olanzapine, risperidone and quetiapine drugs in dementia patients with behavioral and psychological symptoms. Methods: The EMBASE, Cochrane Controlled Trials Register and the Cochrane Database of Systematic Reviews, Medline, CNKI, Wang Fang were systematically searched for eligible randomized controlled trials of olanzapine, risperidone and quetiapine drugs therapy in patients with psychotic symptoms of dementia before February 2016. Two reviewers independently assessed the quality of the trials and extracted information...
July 3, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Kerstin Schweyer, Johannes Levin, Günter U Höglinger
Atypical Parkinson syndromes are a heterogeneous group of neurodegenerative diseases which present with parkinsonism and other non-motor symptoms. On the basis of the underlying pathology, namely the abnormal aggregation of the proteins alpha-synuclein or tau, atypical Parkinson syndromes can be divided into synucleinopathies (multiple system atrophy, Lewy body dementia) and tauopathies (progressive supranuclear palsy, corticobasal degeneration). Currently there are no effective treatments to slow down disease progression available...
July 11, 2018: Fortschritte der Neurologie-Psychiatrie
F Nobili, J Arbizu, F Bouwman, A Drzezga, F Agosta, P Nestor, Z Walker, M Boccardi
BACKGROUND AND PURPOSE: Recommendations for using fluorodeoxyglucose positron emission tomography (FDG-PET) to support the diagnosis of dementing neurodegenerative disorders are sparse and poorly structured. METHODS: Twenty-one questions on diagnostic issues and on semi-automated analysis to assist visual reading were defined. Literature was reviewed to assess study design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiver operating characteristic curve, and positive/negative likelihood ratio of FDG-PET in detecting the target conditions...
June 22, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Koji Kasanuki, Keith A Josephs, Tanis J Ferman, Melissa E Murray, Shunsuke Koga, Takuya Konno, Nobutaka Sakae, Adam Parks, Ryan J Uitti, Jay A Van Gerpen, Neill R Graff-Radford, Zbigniew K Wszolek, Dennis W Dickson
OBJECTIVE: To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS). METHODS: In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intracytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex...
July 17, 2018: Neurology
Kaoru Shinkawa, Yasunori Yamada
For detecting early signs of dementia, monitoring technology has been actively investigated due to the low diagnostic coverage as well as the requirement for early intervention. Although language features have been used for detecting the language dysfunctions resulting from dementia in neuropsychological tests, features that can be extracted by regular conversations remain unexplored. Here, we propose a feature to characterize the atypical repetition of words on different days which is observed in patients with dementia...
2018: AMIA Summits on Translational Science Proceedings
Emme Chacko, Stephen Boyd, Rinki Murphy
ABSTRACTBackground:The atypical antipsychotics (AAPs) are associated with a recognized class effect of glucose and lipid dysregulation. The use of these medications is rapidly increasing in elderly patients with, and without, dementia. However, the metabolic risks specific to elderly remain poorly studied. METHODS: Design: A case-control study. SETTING: Psychogeriatric service in Auckland, New Zealand. PARTICIPANTS: Elderly patients either receiving AAP treatment (cases) or not (controls) between 1 Jan 2008 and 1 Jan 2014...
May 25, 2018: International Psychogeriatrics
C H W Smeets, S U Zuidema, T A Hulshof, M Smalbrugge, D L Gerritsen, R T C M Koopmans, H J Luijendijk
OBJECTIVE: Postulating that efficacy of antipsychotics for agitation and psychosis in dementia is best estimated in trials among patients with these symptoms and with symptom-specific outcomes, we investigated whether clinically broader definitions affected the pooled efficacy. STUDY DESIGN AND SETTING: Trials were searched in multiple databases and categorized according to patient population (agitated, psychotic, mixed) and outcome scale (agitation, psychosis, generic)...
May 18, 2018: Journal of Clinical Epidemiology
Zuzana Walker, Federica Gandolfo, Stefania Orini, Valentina Garibotto, Federica Agosta, Javier Arbizu, Femke Bouwman, Alexander Drzezga, Peter Nestor, Marina Boccardi, Daniele Altomare, Cristina Festari, Flavio Nobili
PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome. METHODS: We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size...
July 2018: European Journal of Nuclear Medicine and Molecular Imaging
V Camacho, A Gómez-Grande, P Sopena, D García-Solís, M Gómez Río, C Lorenzo, S Rubí, J Arbizu
Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aβ1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18 F-FDG PET and temporal atrophy on MRI)...
May 15, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
Anouke van Rumund, Marjolein B Aerts, Rianne A J Esselink, Frederick J A Meijer, Marcel M Verbeek, Bastiaan R Bloem
BACKGROUND: Differentiation of Parkinson's disease (PD) from the various types of atypical parkinsonism (AP) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), corticobasal syndrome (CBS) and vascular parkinsonism (VP), can be challenging, especially early in the disease course when symptoms overlap. A major unmet need in the diagnostic workup of these disorders is a diagnostic tool that differentiates the various disorders, preferably in the earliest disease stages when the clinical presentation is similar...
May 16, 2018: BMC Neurology
Chin-Hsien Lin, Shieh-Yueh Yang, Herng-Er Horng, Che-Chuan Yang, Jen-Jie Chieh, Hsin-Hsien Chen, Bing-Hsien Liu, Ming-Jang Chiu
Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples ( n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism...
2018: Frontiers in Aging Neuroscience
Peter J Nestor, Daniele Altomare, Cristina Festari, Alexander Drzezga, Jasmine Rivolta, Zuzana Walker, Femke Bouwman, Stefania Orini, Ian Law, Federica Agosta, Javier Arbizu, Marina Boccardi, Flavio Nobili, Giovanni Battista Frisoni
AIM: To assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer's disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia. METHODS: A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method...
May 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Gabriele Cipriani, Angelo Nuti, Sabrina Danti, Lucia Picchi, Mario Di Fiorino
Clinical neurologists have long recognized that dementia can present as atypical or variant syndromes/symptoms. This study aimed at describing uncommon or bizarre symptoms/syndromes observed in patients suffering from dementia. Medline and Google scholar searches were conducted for relevant articles, chapters, and books published before 2018. Search terms used included compulsion, dementia, extracampine hallucination, disordered gambling, humour, and obsession. Publications found through this indexed search were reviewed for further relevant references...
June 2018: Acta Neurologica Belgica
Alejandro G Szmulewicz, Augusto Ferraris, Agustín Rodriguez, Lucía Campos Cervera, Macarena Lopez Gonzalez, Federico Man, Federico Angriman, Diego Martino
We aimed to compare the mortality risk between patients with affective disorders and dementia under treatment with antipsychotics. To do this, a matched-cohort study based on an electronic database of a tertiary teaching hospital in Argentina was performed. Antipsychotic exposure was defined as any antipsychotic drug initiated by the patient. Primary outcome was defined as all-cause mortality during the 5-year follow-up period. To estimate the association between baseline diagnosis (affective disorders vs. dementia) and all-cause mortality, we used a multivariate generalized linear model with robust standard errors...
July 2018: Psychiatry Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"